Tuesday’s analyst upgrades and downgrades
The analyst made one change, raising his target for Quebecor Inc. ( QBR-B-T unch ) to $45 from $40, keeping a “buy” rating. The average target on the Street is $39.04, according to LSEG data.
Cytosorbents outlines 2025 growth strategy with $1B market potential for DrugSorb-ATR
Cytosorbents Corporation (CTSO) reports 25% Q4 revenue growth, strong margins, and updates on FDA-reviewed DrugSorb-ATR launch.
UBS lowers its year-end S&P target but says it still foresees meaningful upside
UBS lowers S&P 500 year-end target amid tariff concerns and market volatility, but highlights upside from US growth and AI ...
Wednesday’s analyst upgrades and downgrades
In a note released Wednesday, Mr. Treiber said the firm’s RBC Elements predictive model suggests a 95-per-cent confidence ...